Indivior (NASDAQ:INDV) Sets New 52-Week High - Should You Buy?

Key Points

• Indivior PLC shares reached a new 52-week high of $25.00 during trading, indicating strong market performance with a trading volume of 198,644 shares.
• Analysts are optimistic about Indivior, with a consensus rating of “Buy” and some firms issuing price targets as high as $27.00.
• In its latest earnings report, Indivior reported $0.51 earnings per share, significantly exceeding expectations and showcasing a revenue of $302 million.

Indivior PLC (NASDAQ:INDV - Get Free Report) hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $25.00 and last traded at $24.48, with a volume of 198644 shares. The stock had previously closed at $24.46.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on INDV shares. Craig Hallum raised their price target on Indivior from $27.00 to $34.00 and gave the stock a "buy" rating in a report on Wednesday. Jefferies Financial Group started coverage on Indivior in a report on Tuesday, July 22nd. They issued a "buy" rating and a $20.00 price target on the stock. HC Wainwright started coverage on Indivior in a report on Wednesday, August 6th. They issued a "buy" rating and a $27.00 price target on the stock. Finally, Wall Street Zen raised Indivior from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 21st. One analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $22.00.

Indivior Stock Performance

The firm has a 50 day simple moving average of $18.83 and a two-hundred day simple moving average of $13.56.

Indivior (NASDAQ:INDV - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.25. The firm had revenue of $302.00 million for the quarter, compared to the consensus estimate of $239.43 million. Indivior had a negative return on equity of 86.28% and a net margin of 6.65%. Indivior has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Institutional Trading of Indivior

Several hedge funds have recently added to or reduced their stakes in the business. Nomura Holdings Inc. bought a new stake in Indivior during the 2nd quarter valued at $7,602,000. Tower Research Capital LLC TRC raised its stake in Indivior by 851.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 10,567 shares of the company's stock valued at $156,000 after acquiring an additional 9,456 shares in the last quarter. Krensavage Asset Management LLC raised its stake in Indivior by 0.9% during the 2nd quarter. Krensavage Asset Management LLC now owns 974,474 shares of the company's stock valued at $14,364,000 after acquiring an additional 9,106 shares in the last quarter. Rubric Capital Management LP raised its stake in shares of Indivior by 31.6% in the 2nd quarter. Rubric Capital Management LP now owns 4,647,179 shares of the company's stock worth $68,499,000 after buying an additional 1,117,140 shares in the last quarter. Finally, Gendell Jeffrey L raised its stake in shares of Indivior by 41.2% in the 2nd quarter. Gendell Jeffrey L now owns 856,481 shares of the company's stock worth $12,625,000 after buying an additional 250,000 shares in the last quarter. Institutional investors own 60.33% of the company's stock.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.